BRIDGEWATER, N.J., Sept. 1, 2017 /PRNewswire-USNewswire/
-- Sanofi announced today that the U.S. Food and Drug
Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting
human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
The tentative approval is based on physicochemical, non-clinical and clinical similarity to another insulin lispro 100
Units/mL as currently approved in the U.S., including data from a clinical development program involving more than 1,000 adults
living with type 1 or type 2 diabetes. Admelog is contraindicated during episodes of hypoglycemia and in patients with
hypersensitivity to insulin lispro or one of its other ingredients.
With the tentative approval, the FDA concluded that Admelog met all necessary regulatory requirements for approval in the
U.S., pending any patent issues that are yet to be resolved.
"Sanofi is committed to broadening our portfolio of products to help people living with diabetes manage their blood
sugar," said Stefan Oelrich, Senior Vice President and Head, Global Diabetes Franchise,
Sanofi. "With this tentative approval, we are now one step closer to offering Admelog as an option for those who use
rapid-acting insulin."
The trade name "Admelog" was granted provisional approval by the FDA and will be used in the U.S. when the product is made
available. Admelog was also granted marketing authorization under the proprietary name, Insulin lispro Sanofi, by the European
Commission in July 2017.
About Sanofi Diabetes & Cardiovascular
Diabetes and cardiovascular disease affect millions of people worldwide, with many managing the complex challenges of
both. Building on our portfolio evolution, heritage and expertise, Sanofi has a focused business unit dedicated to delivering
innovative, value-based medicines and integrated solutions in these therapeutic areas. We are committed to a collaborative
approach that involves strategic alliances with professional and patient associations, research institutions and leaders in
healthcare and other industries, with the goal of advancing scientific knowledge, driving the convergence of science and
technology, helping to improve outcomes and inspiring an evolution in care.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients'
needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets,
Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and
estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or
government regulation generally, that could affect the availability or commercial potential of the product, the absence of
guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including
future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety,
quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future
litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or
identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended
December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
View original content:http://www.prnewswire.com/news-releases/sanofi-receives-tentative-fda-approval-of-admelog-insulin-lispro-injection-100-unitsml-300513105.html
SOURCE Sanofi